Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
16-week randomized double-blind placebo-controlled dose-finding study of subcutaneous AIN457 in rheumatoid arthritis with methotrexate, with extension to 60 weeks
2009-011000-34Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Subcutaneous AIN457 plus methotrexate with Placebo plus methotrexate (2 arms). Primary endpoint: ACR20 response at 16 weeks. Started Jun 2009; status: completed.
02
Drugs
secukinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2009-011000-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011000-34.